ERVMER34-1 encodes an endogenous retroviral envelope protein derived from ancient retroviral integration approximately 100 million years ago 1. Originally functioning as a fusogenic envelope protein mediating membrane fusion, ERVMER34-1 has lost its furin cleavage site and fusion peptide during evolution, becoming nonfusogenic 1. In normal physiology, ERVMER34-1 is expressed as a syncytin family member in human placental trophoblast, where it functions as a probable negative regulator of cell-cell fusion, co-expressed primarily in cytotrophoblast 2. The protein is secreted as a soluble SHED form and can interact with BACE2 (β-site APP-cleaving enzyme 2), a partnership that evolved in the primate lineage 30-45 million years ago 1. In cancer, ERVMER34-1 is aberrantly overexpressed in 232/376 human carcinomas while remaining absent in most healthy adult tissues 3. High ERVMER34-1 expression associates with poor survival in uveal melanoma, adenoid cystic carcinoma, and head and neck cancers 3. Functionally, ERVMER34-1 appears linked to oncogenic roles in breast cancer and colon adenocarcinoma 45. ERVMER34-1-specific T cells effectively lyse carcinoma cells expressing the protein, supporting therapeutic vaccine development as an emerging immunotherapeutic strategy for cancer treatment 3.